Aceso Takes Center Stage at the 2026 ASCO Meeting, Showcasing Chinese Bio Innovation
Aceso's Plenary Session Entry
Aceso presented ivonescimab data in a plenary session at ASCO 2026. This marks the first Chinese data set to secure a key slot on the international stage, underscoring its significance. It reflects that Chinese biotech companies' research capabilities are approaching global standards.
Significance of ivonescimab and Cell Therapy
ivonescimab is an antibody‑based cell therapy, a biologic administered directly to patients. It is expected to be a high‑objective response rate (ORR) treatment. A high ORR serves as an objective metric of therapeutic efficacy, providing substantial value in clinical practice.
Leap of the Chinese Biotech Industry
Since the success of Nanjing Legend Biotech’s Carvykti in 2017, Aceso now follows suit. Chinese firms are leading global clinical trials from early stages, driven by government support and expanded investment. This offers new growth drivers for investors worldwide.
Impact on Market and Patients
The plenary presentation opens the door for other Chinese companies to disclose clinical data. For patients, it expands access to innovative therapies; for the market, competition is expected to improve pricing and accessibility. Consequently, diversification of the overall biotech market is accelerating.
Aceso’s plenary announcement raises the credibility of Chinese biotech companies’ clinical data, substantially increasing their global investment appeal—a critical value point for investors. With rapid growth in China’s biotech research infrastructure and talent demand, new opportunities are emerging for job seekers and industry professionals.